Literature DB >> 12393524

Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell.

Tiemo Katzenberger1, Andreas Lohr, Stephan Schwarz, Martin Dreyling, Julia Schoof, Christina Nickenig, Stephan Stilgenbauer, Jörg Kalla, M Michaela Ott, Hans Konrad Müller-Hermelink, German Ott.   

Abstract

CD5(+) diffuse large B-cell lymphomas (DLBLs) have recently been described as a particular subgroup of DLBLs. Classical banding and interphase cytogenetic analyses targeting ATM, TP53, and P16(INK4a) genes and the D13S25 locus from 13 CD5(+) DLBLs were compared with 55 CD5(-) DLBLs. Additionally, analysis of somatic mutations of the immunoglobulin heavy chain variable region (IgVH) genes were performed in CD5(+) DLBLs. CD5(+) DLBLs were somatically mutated (7 of 8 cases) and were negative for t(11;14)(q13;q32) and t(14;18)(q32;q21), whereas t(3;14)(q27;q32) was found in only one tumor. Trisomy 3 and gains on chromosomes 16/16p and 18/18q were significantly overrepresented in CD5(+) DLBLs. No ATM deletions were detected. The prevalence of deletions at the D13S25 locus was significantly higher in CD5(+) DLBLs (4 of 12 [33%]) compared with CD5(-) DLBLs (4 of 42 [10%]), as were p16(INK4a) deletions (33% versus 8%). On the basis of these findings, CD5(+) DLBLs are likely to arise from the same progenitor cell as the mutated variant of CD5(+) lymphocytic lymphoma/B-cell chronic lymphocytic leukemia (B-CLL).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393524     DOI: 10.1182/blood-2002-06-1726

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region.

Authors:  Naoya Nakamura; Shigeo Nakamura; Motoko Yamaguchi; Ryo Ichinohasama; Tadashi Yoshino; Tetsuo Kuze; Yoshikazu Sasaki; Sachiko Yoshida; Masafumi Abe
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

2.  Primary splenic diffuse large B-cell lymphoma manifesting in red pulp.

Authors:  Makoto Kashimura; Masahiro Noro; Bunshiro Akikusa; Atsushi Okuhara; Shuji Momose; Ikuo Miura; Masaru Kojima; Jun-Ichi Tamaru
Journal:  Virchows Arch       Date:  2008-09-26       Impact factor: 4.064

3.  Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study.

Authors:  Zi Chen; Zunguo Du; Jieqing Chen; Zhongqing Chen; Yun Bao; Feng Tang
Journal:  Med Oncol       Date:  2010-02-18       Impact factor: 3.064

4.  De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.

Authors:  Sun-Young Kong; Eun Hae Cho; Hee Yeon Woo; Qeuhn Park; Young Hyeh Ko; Sun-Hee Kim
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

5.  Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.

Authors:  Alexandar Tzankov; Philip Went; Stephan Dirnhofer
Journal:  Biomark Insights       Date:  2007-11-11

6.  Serum interleukin-10 as a valuable biomarker for early diagnosis and therapeutic monitoring in intravascular large B-cell lymphoma.

Authors:  Yan Zhang; Liang Wang; Jian Sun; Wei Wang; Chong Wei; Daobin Zhou; Wei Zhang
Journal:  Clin Transl Med       Date:  2020-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.